David Bekhor, MD
Infectious Disease · New York, NYNPI 1194797837
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $294,926 of the $357,775 with a category attached, or 82.4%. 33 manufacturers reported payments, led by Viiv Healthcare Company at 56.6% of the total. Among infectious disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 960 payments — averaging $372.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$202K
- Gilead$147K
- Johnson & Johnson$2K
- AbbVie$1K
- Janssen Products, LP$1K
- Merck$993
- plus $3K from 27 others
What the payments were for
- Consulting fees$15,2004%
- Speaking & faculty fees$294,92682%
- Travel & lodging$18,8115%
- Food & beverage$28,7998%
- Education$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 320 | $202,413 |
| Gilead | 360 | $147,362 |
| Johnson & Johnson | 65 | $1,786 |
| AbbVie(2 entities) | 87 | $1,454 |
| Janssen Products, LP | 10 | $1,180 |
| Merck | 43 | $993 |
| Bavarian Nordic A/s | 3 | $397 |
| GSK | 4 | $295 |
| Shionogi Inc | 10 | $274 |
| Melinta Therapeutics, LLC | 10 | $230 |
| Axsome Therapeutics, Inc. | 6 | $147 |
| Amgen | 1 | $125 |
| Eisai Inc. | 1 | $124 |
| Hologic Sales And Service, LLC | 3 | $108 |
| Theratechnologies Inc. | 4 | $105 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $86 |
| Sanofi-aventis U.S. LLC | 4 | $80 |
| Otsuka America Pharmaceutical, Inc. | 3 | $74 |
| Idorsia Pharmaceuticals US Inc | 4 | $67 |
| Paratek Pharmaceuticals, Inc. | 3 | $60 |
| Aimmune Therapeutics, Inc. | 2 | $53 |
| Novo Nordisk | 3 | $50 |
| Napo Pharmaceuticals Inc | 2 | $47 |
| Shield Therapeutics Inc | 2 | $44 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Cleerly, Inc. | 1 | $30 |
| Philips North America LLC | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Pfizer | 1 | $25 |
| Lundbeck LLC | 1 | $22 |
| EMD Serono, Inc. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$357,775 in reported general payments places this provider in the 95th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 127 | $511,697 |
| DescovyEmtricitabine/Tenofov Alafenam | 19 | $50,191 |
| Maraviroc | 16 | $39,515 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $35,147 |
| EdurantRilpivirine Hcl | 12 | $16,234 |
| Darunavir | 12 | $9,555 |
| Abacavir-LamivudineAbacavir Sulfate/Lamivudine | 16 | $1,576 |
| Atorvastatin Calcium | 126 | $569 |
| ValacyclovirValacyclovir Hcl | 21 | $565 |
| Nifedipine ErNifedipine | 16 | $346 |
| Bupropion XlBupropion Hcl | 12 | $333 |
| Rosuvastatin Calcium | 18 | $210 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $206 |
| Simvastatin | 11 | $206 |
| Levothyroxine Sodium | 36 | $174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $147,362 | $561,888146 claims |
| Viiv Healthcare CompanyDovato | $202,413 | $35,14712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 799 infectious disease providers in New York.
Other infectious disease in New York
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- Genovefa PapanicolaouNew York$209K
- Michelle CespedesNew York$125K
- Donald KaminskyNew York$120K
- Judith AbergNew York$104K
- Thomas WalshNew York$98K
- Stuart HaberNew York$73K
- Michael GaisaNew York$47K
- Joseph FeczkoNew York$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.